Transcriptomics: mRNA and alternative splicing

Journal of Neuroimmunology

Volumn 248, Issue 1-2, 2012, Pages 23-31

  Sánchez Pla, Alex ^a,b   Reverter, Ferran ^a   Ruíz de Villa, M Carme ^a   Comabella, Manuel ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Hospital Universitari Vall dD Hebron (VHIR)   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Alternative splicing; Bioinformatics; Microarrays; Multiple sclerosis; Next generation sequencing; Transcriptomics

Indexed keywords

MESSENGER RNA; TRANSCRIPTOME;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOINFORMATICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TECHNOLOGY; HUMAN; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RNA HYBRIDIZATION; RNA SEQUENCE; SEQUENCE ANALYSIS; TRANSCRIPTOMICS;

ALTERNATIVE SPLICING; ANIMALS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MULTIPLE SCLEROSIS; RNA, MESSENGER;

EID: 84862594116     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.04.008     Document Type: Article

References (72)

1. Achiron Anat, et al. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 2004, 55(3):410-417.
2. Achiron Anat, et al. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann. N. Y. Acad. Sci. 2007, 1107:155-167.
3. Achiron Anat, Feldman A., Gurevich Michael Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis. Markers 2009, 27(2):63-73.
4. Allison D.B., et al. Microarray data analysis: from disarray to consolidation and consensus. Nat. Rev. Genet. 2006, 7(1):55-65.
5. Arthur Ariel T., et al. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. BMC Med. Genet. 2008, 9(1):17.
6. Bertone P., Stolc V., Royce T.E., Rozowsky J.S., Urban A.E., Zhu X., Rinn J.L., Tongprasit W., Samanta M., Weissman S., Gerstein M., Snyder M. Global identification of human transcribed sequences with genome tiling arrays. Science 2004, 306:2242-2246.
7. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72:291-336.
8. Bomprezzi R., et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 2003, 12(17):2191-2199.
9. Booth D.R., et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J. Mol. Med. 2005, 83(10):822-830.
10. Castaldi P.J., Dahabreh I.J., Ioannidis J.P.A. An empirical assessment of validation practices for molecular classifiers. Brief. Bioinform. 2011, 12(3):189-202.
11. Comabella Manuel, Martin Roland Genomics in multiple sclerosis-current state and future directions. J. Neuroimmunol. 2007, 187(1-2):1-8.
12. Comabella M., et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain: J. Neurol. 2009, 132(Pt 12):3353-3365.
13. Corvol J.-C., Pelletier D., Henry R.G., et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(33):11839-11844.
14. Croze E. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res. 2010, 30(10):743-749.
15. Dalma-Weiszhausz D.D., et al. The affymetrix GeneChip platform: an overview. Methods Enzymol. 2006, 410:3-28.
16. Dudoit S., Shaffer J.P., Boldrick J.C. Multiple hypothesis testing in microarray experiments. Statistical Science 2003, 18:71-103.
17. Duggan D.J., et al. Expression profiling using cDNA microarrays 1999, Nature America Inc.
18. Dupuy A., Simon R.M. Critical Review of Published Microarray Studies for Cancer Outcome and Guidelines on Statistical Analysis and Reporting. JNCI J. Natl. Cancer Inst. 2007, 99(2):147.
19. Encode P.C. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004, 306(5696):636-640.
20. Gerstein M.B., et al. What is a gene, post-ENCODE? History and updated definition. Genome Res. 2007, 17(6):669-681.
21. Gevaert O., De Moor B. Prediction of cancer outcome using DNA microarray technology: past, present and future. Expert Opin. Med. Diagn. 2009, 3:157-165.
22. Goertsches Robert H., et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010, 11(2):147-161.
23. Graumann U., et al. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 2003, 13(4):554-573.
24. Hall M.A. Correlation-based Feature Selection for Machine Learning Available at:. http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.37.4643.
25. Hecker M., et al. Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment. Pharmacogenomics J. 2010, Available at: http://www.ncbi.nlm.nih.gov/pubmed/20956993 [Accessed January 24, 2012].
26. Hong J., et al. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J. Neuroimmunol. 2004, 152(1-2):126-139.
27. Hurd P.J., Nelson C.J. Advantages of next-generation sequencing versus the microarray in epigenetic research. Brief. Funct. Genomic. Proteomic. 2009, 8(3):174-183.
28. Iglesias A.H., Camelo S., Hwang D., Villanueva R., Stephanopoulos G., Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 2004, 150:163-177.
29. Infante-Duarte C., et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2005, 19(13):1902-1904.
30. Jelinsky S.A., et al. Exploiting genotypic differences to identify genes important for EAE development. J. Neurol. Sci. 2005, 239(1):81-93.
31. Kendziorski C., et al. On the utility of pooling biological samples in microarray experiments. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(12):4252-4257.
32. Kerr M.K., Churchill G.A. Experimental design for gene expression microarrays. Biostatistics 2001, 2(2):183-201. (Jun).
33. Koike F., et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J. Neuroimmunol. 2003, 139(1-2):109-118.
34. Kolle Gabriel Microarrays and alternative splicing ASBMB 38 (3) (December). Available at:. http://www.asbmb.org.au/magazine/2007-December_Issue38-3/Technical%20Feature%202%20-%20Kolle.pdf.
35. Ledford H. The death of microarrays?. Nature 2008, 455(7215):847.
36. Lee M.-L.T., et al. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc. Natl. Acad. Sci. 2000, 97(18):9834-9839.
37. Lee J., et al. An extensive comparison of recent classification tools applied to microarray data. Comput. Stat. Data Anal. 2005, 48:869-885.
38. Lindberg R.L., Kappos L. Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment. Expert Rev. Mol. Diagn. 2006, 6(6):843-855.
39. Lindberg R.L.P., De Groot C.J.A., et al. Multiple sclerosis as a generalized CNS disease-comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J. Neuroimmunol. 2004, 152(1-2):154-167.
40. Lindberg R.L.P., et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J. Neuroimmunol. 2008, 194(1-2):153-164.
41. Lipshutz R.J., et al. High density synthetic oligonucleotide arrays 1999, Nature America Inc.
42. Lock C., Hermans G., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8(5):500-508.
43. Mandel M., et al. Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin. Exp. Immunol. 2004, 138(1):164-170.
44. Maxam A.M., Gilbert W. A new method for sequencing DNA. Proc. Natl. Acad. Sci. U. S. A. 1977, 74(2):560-564.
45. Metzker M.L. Sequencing technologies - the next generation. Nat. Rev. Genet. 2010, 11(1):31-46.
46. Munro K.M., Perreau V.M. Current and future applications of transcriptomics for discovery in CNS disease and injury. Neurosignals 2009, 17(4):311-327.
47. Mycko M.P., Papoian R., et al. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain: J. Neurol. 2003, 126(Pt 5):1048-1057.
48. Mycko M.P., et al. Microarray gene expression profiling of chronic active and inactive lesions in multiple sclerosis. Clin. Neurol. Neurosurg. 2004, 106(3):223-229.
49. Nguyen D.V. DNA microarray experiments: biological and technological aspects. Biometrics 2002, 58:701-717.
50. Ramanathan M., et al. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 2001, 116(2):213-219.
51. Rudick R.A., et al. Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis. PLoS One 2011, 6(5):e19262.
52. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1977, 74(12):5463-5467.
53. Satoh J. Bioinformatics approach to identifying molecular biomarkers and networks in multiple sclerosis. Clin. Exp. Neuroimmunol. 2010, 1(3):127-140.
54. Satoh J.-ichi, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol. Dis. 2005, 18(3):537-550.
55. Schena M., et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270(5235):467-470.
56. Serrano-Fernández P., et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 2010, 43(2):172-178.
57. Simon Richard M., et al. Design and Analysis of DNA Microarray Investigations 2003, Springer-Verlag.
58. Skotheim R.I., Nees M. Alternative splicing in cancer: noise, functional, or systematic?. Int. J. Biochem. Cell Biol. 2007, 39(7-8):1432-1449.
59. Smith G.W., Rosa G.J.M. Interpretation of microarray data: trudging out of the abyss towards elucidation of biological significance. J. Anim. Sci. 2007, 85(Suppl. 13):E20-E23.
60. Stürzebecher S., Wandinger K.P., et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain: J. Neurol. 2003, 126(Pt 6):1419-1429.
61. Tago C., Okamoto M., Hanai T. Prognosis prediction by microarray gene expression using support vector machine. Genome Inform. 2003, 14:324-325.
62. Tajouri L., et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res. Mol. Brain Res. 2003, 119(2):170-183.
63. Tian Y., et al. Differences in exon expression and alternatively spliced genes in blood of multiple sclerosis compared to healthy control subjects. J. Neuroimmunol. 2011, 230(1-2):124-129.
64. Tibshirani R., et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. 2002, 99(10):6567-6572.
65. van Baarsen L.G.M., et al. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun. 2006, 7(6):522-531.
66. van Baarsen Lisa G.M., et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008, 3(4):e1927.
67. Wandinger K.P., Stürzebecher C.S., et al. Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann. Neurol. 2001, 50(3):349-357.
68. Wang Z., Gerstein M., Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 2009, 10(1):57-63.
69. Weinstock-Guttman B., et al. Genomic effects of IFN-beta in multiple sclerosis patients. J. Immunol. 2003, 171(5):2694-2702.
70. Whitney L.W., et al. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 1999, 46(3):425-428.
71. Whitney L.W., Ludwin S.K., McFarland H.F., Biddison W.E. Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions. J. Neuroimmunol. 2001, 121:40-48.
72. Zhao Y., Gran B., et al. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J. Immunol. 2001, 167(4):2130-2141.